Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
S Reis, MI Metzendorf, R Kuehn… - Cochrane Database …, 2023 - cochranelibrary.com
Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …
[HTML][HTML] Key considerations during the transition from the acute phase of the COVID-19 pandemic: a narrative review
P Rzymski, M Pokorska-Śpiewak, T Jackowska… - Vaccines, 2023 - mdpi.com
The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …
community, leading to the development, investigation, and authorization of vaccines and …
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study
H Wang, Y Wei, CT Hung, G Lin, X Jiang… - The Lancet Infectious …, 2024 - thelancet.com
Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
[HTML][HTML] Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
I Karniadakis, N Mazonakis, C Tsioutis… - Infectious Disease …, 2023 - mdpi.com
Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …
[HTML][HTML] Determining and comparing the real-world effectiveness of molnupiravir and nirmatrelvir-ritonavir in patients hospitalized with COVID-19
YR Jang, Y Oh, JY Kim - Journal of Korean Medical Science, 2024 - ncbi.nlm.nih.gov
Background Current guidelines recommend using nirmatrelvir-ritonavir for coronavirus
disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications …
disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications …
[HTML][HTML] Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study
Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …
[HTML][HTML] Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
S Wang, J Sun, X Zhang, M Li, B Qin, M Liu… - …, 2024 - thelancet.com
Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
[HTML][HTML] Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
AA Butt, P Yan, OS Shaikh - Plos one, 2024 - journals.plos.org
Background In randomized controlled trials, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …
(MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited …
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
S Ombelet, D Castanares‐Zapatero… - Journal of Medical …, 2024 - Wiley Online Library
Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …